YiChang HEC ChangJiang Pharmaceutical Future Growth

YiChang HEC ChangJiang Pharmaceutical is forecast to grow revenue at 2% per annum.

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	10.8%
Revenue growth rate	2.0%
Future return on equity	18.6%
Analyst coverage	Low
Last updated	16 Sep 2024

No updates

Earnings and Revenue Growth Forecasts

SHSC:1558 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	5,780	N/A	N/A	N/A	1
12/31/2025	5,620	N/A	N/A	N/A	1
12/31/2024	5,444	N/A	N/A	N/A	1
6/30/2024	5,540	1,648	-398	453	N/A
3/31/2024	5,917	1,820	340	1,063	N/A
12/31/2023	6,295	1,993	1,078	1,673	N/A
9/30/2023	5,978	1,566	1,604	2,233	N/A
6/30/2023	5,661	1,139	2,130	2,792	N/A
3/31/2023	4,703	608	1,488	2,246	N/A
12/31/2022	3,745	77	847	1,700	N/A
9/30/2022	2,875	-18	108	826	N/A
6/30/2022	2,005	-113	-630	-48	N/A
3/31/2022	1,459	-351	-936	-355	N/A
12/31/2021	914	-588	-1,242	-663	N/A
9/30/2021	690	-436	-1,544	-582	N/A
6/30/2021	467	-285	-1,845	-501	N/A
3/31/2021	1,407	277	-1,232	399	N/A
12/31/2020	2,348	839	-619	1,299	N/A
9/30/2020	3,792	1,204	-23	1,688	N/A
6/30/2020	5,236	1,568	574	2,076	N/A
3/31/2020	5,730	1,743	348	1,935	N/A
12/31/2019	6,224	1,919	122	1,794	N/A
9/30/2019	5,162	1,598	-282	1,468	N/A
6/30/2019	4,099	1,276	-686	1,141	N/A
3/31/2019	3,305	1,109	-534	928	N/A
12/31/2018	2,510	943	-381	715	N/A
9/30/2018	2,466	961	-15	878	N/A
6/30/2018	2,422	980	351	1,041	N/A
3/31/2018	2,012	813	N/A	856	N/A
12/31/2017	1,602	647	N/A	671	N/A
9/30/2017	1,325	557	N/A	546	N/A
6/30/2017	1,048	467	N/A	422	N/A
3/31/2017	995	424	N/A	409	N/A
12/31/2016	942	381	N/A	397	N/A
9/30/2016	904	354	N/A	391	N/A
6/30/2016	866	327	N/A	385	N/A
3/31/2016	779	297	N/A	336	N/A
12/31/2015	693	266	N/A	287	N/A
9/30/2015	637	236	N/A	196	N/A
6/30/2015	581	207	N/A	104	N/A
3/31/2015	511	171	N/A	117	N/A
12/31/2014	441	135	N/A	130	N/A
12/31/2013	316	58	N/A	52	N/A

Earnings vs Savings Rate: Insufficient data to determine if 1558's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 1558's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1558's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1558's revenue (2% per year) is forecast to grow slower than the Hong Kong market (7.8% per year).

High Growth Revenue: 1558's revenue (2% per year) is forecast to grow slower than 20% per year.

Future ROE: 1558's Return on Equity is forecast to be low in 3 years time (18.6%).